论文部分内容阅读
目的 :探索卡培他滨联合奥沙利铂治疗老年进展期胃癌的疗效。方法 :选择96例进展期老年胃癌患者为研究对象,采用随机数字表法将其分为两组,对照组48例予卡培他滨(1 500 mg/m~2,bid)治疗,观察组48例予卡培他滨(1 500 mg/m~2,bid)联合奥沙利铂(130 mg/m~2,qd)治疗,两组比较临床疗效及安全性。结果 :观察组总有效率明显高于对照组(P<0.05)。治疗后两组患者生活质量各维度评分及总评分均较治疗前明显增加,且观察组明显高于对照组,差异有统计学意义(P<0.05)。两组不良反应情况比较无统计学意义(P>0.05)。结论 :卡培他滨联合奥沙利铂治疗老年进展期胃癌疗效显著,可有效改善生活质量,安全可靠。
Objective: To investigate the curative effect of capecitabine combined with oxaliplatin in the treatment of advanced gastric cancer. Methods: Ninety-six elderly patients with advanced gastric cancer were enrolled in this study. They were divided into two groups according to the random number table. The control group was treated with capecitabine (1 500 mg / m ~ 2, bid) 48 cases were treated with capecitabine (1 500 mg / m 2, bid) and oxaliplatin (130 mg / m 2, qd). The clinical efficacy and safety of the two groups were compared. Results: The total effective rate in observation group was significantly higher than that in control group (P <0.05). After treatment, the scores of quality of life and the total score of both groups were significantly higher than those before treatment, and the observation group was significantly higher than the control group, the difference was statistically significant (P <0.05). Adverse reactions between the two groups were not statistically significant (P> 0.05). Conclusion: Capecitabine and oxaliplatin are effective in treating elderly patients with advanced gastric cancer, which can effectively improve the quality of life and are safe and reliable.